Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)

Organization
NCI
Type
NIH
Application or LOI Due Date
11-15-2020
Number
RFA-CA-20-046
Comments
LOI required and due 11/15/20 for application due date of 12/15/20.
Brief Description

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.